Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to aging and improve the functional results of patients suffering from related illnesses, announces having received a notice of delisting from Nasdaq.
Accordingly, the Company intends to request a hearing before the Committee. The request for hearing will automatically stay any suspension or disbarment action pending the hearing. Pursuant to Nasdaq listing rules, the panel has the discretion to grant the company an additional extension not later than April 23, 2024. At the hearing, the company plans to present its plan to regain and maintain compliance to the applicable equity requirement for continued listing.